Search Results - "MANOLAKOPOULOS, S."

Large Balloon Dilation vs. Mechanical Lithotripsy for the Management of Large Bile Duct Stones: A Prospective Randomized Study by STEFANIDIS, G, VIAZIS, N, KATSIKANI, A, CHUTTANI, R, PLESKOW, D, MANOLAKOPOULOS, S, THEOCHARIS, L, CHRISTODOULOU, C, KOTSIKOROS, N, GIANNOUSIS, J, SGOUROS, S, RODIAS, M

“…The removal of large bile duct stones (>12 mm) after endoscopic sphincterotomy (EST) remains a challenging issue in therapeutic endoscopy. The aim of this…”
Get full text

Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection by Vassilopoulos, D, Apostolopoulou, A, Hadziyannis, E, Papatheodoridis, G V, Manolakopoulos, S, Koskinas, J, Manesis, E K, Archimandritis, A I

“…The aim of this prospective study was to examine the safety of anti-tumour necrosis factor (TNF) therapy in patients with rheumatic disease and hepatitis B…”
Get more information

Intestinal decontamination improves liver haemodynamics in patients with alcohol‐related decompensated cirrhosis by VLACHOGIANNAKOS, J., SAVERIADIS, A. S., VIAZIS, N., THEODOROPOULOS, I., FOUDOULIS, K., MANOLAKOPOULOS, S., RAPTIS, S., KARAMANOLIS, D. G.

“…Summary Background  Endotoxaemia is commonly seen in cirrhotic patients with ascites and this may be associated with increased portal pressure. Aim  To…”
Get full text

Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate by Papatheodoridis, G., Triantos, C., Hadziyannis, E., Zisimopoulos, K., Georgiou, A., Voulgaris, T., Vlachogiannakos, I., Nikolopoulou, V., Manolakopoulos, S.

“…Summary The kinetics of serum HBsAg and interferon‐inducible protein 10 (IP10) levels in patients with chronic hepatitis B infection treated with tenofovir are…”
Get full text

Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort by Papatheodoridis, G. V., Manolakopoulos, S., Touloumi, G., Nikolopoulou, G., Raptopoulou-Gigi, M., Gogos, C., Vafiadis-Zouboulis, I., Karamanolis, D., Chouta, A., Ilias, A., Drakoulis, C., Mimidis, K., Ketikoglou, I., Manesis, E., Mela, M., Hatzis, G., Dalekos, G. N.

“…Summary Hepatocellular carcinoma (HCC) may still develop in chronic hepatitis B (CHB) patients treated with lamivudine. Whether HCC rates are comparable in…”
Get full text

The role of tenofovir in preventing and treating hepatitis B virus (HBV) reactivation in immunosuppressed patients. A real life experience from a tertiary center by Koskinas, J.S, Deutsch, M, Adamidi, S, Skondra, M, Tampaki, M, Alexopoulou, A, Manolakopoulos, S, Pectasides, D

“…Abstract Introduction/aim Patients who present HBV reactivation during immunosuppressive treatment are prone to develop life threatening decompensation of the…”
Get full text

Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference by Papatheodoridis, G., Thomas, H. C., Golna, C., Bernardi, M., Carballo, M., Cornberg, M., Dalekos, G., Degertekin, B., Dourakis, S., Flisiak, R., Goldberg, D., Gore, C., Goulis, I., Hadziyannis, S., Kalamitsis, G., Kanavos, P., Kautz, A., Koskinas, I., Leite, B. R., Malliori, M., Manolakopoulos, S., Matičič, M., Papaevangelou, V., Pirona, A., Prati, D., Raptopoulou - Gigi, M., Reic, T., Robaeys, G., Schatz, E., Souliotis, K., Tountas, Y., Wiktor, S., Wilson, D., Yfantopoulos, J., Hatzakis, A.

“…Summary In the WHO–EURO region, around 28 million people are currently living with chronic viral hepatitis, and 120 000 people die every year because of it…”
Get full text

The State of Hepatitis B and C in the Mediterranean and Balkan Countries: Report from a Summit Conference by Hatzakis, A., Van Damme, P., Alcorn, K., Gore, C., Benazzouz, M., Berkane, S., Buti, M., Carballo, M., Cortes Martins, H., Deuffic-Burban, S., Dominguez, A., Donoghoe, M., Elzouki, A-N., Ben-Alaya Bouafif, N., Esmat, G., Esteban, R., Fabri, M., Fenton, K., Goldberg, D., Goulis, I., Hadjichristodoulou, T., Hatzigeorgiou, T., Hamouda, O., Hasurdjiev, S., Hughes, S., Kautz, A., Malik, M., Manolakopoulos, S., Matičič, M., Papatheodoridis, G., Peck, R., Peterle, A., Potamitis, G., Prati, D., Roudot-Thoraval, F., Reic, T., Sharara, A., Shennak, M., Shiha, G., Shouval, D., Sočan, M., Thomas, H., Thursz, M., Tosti, M., Trépo, C., Vince, A., Vounou, E., Wiessing, L., Manns, M.

“…Summary The burden of disease due to chronic viral hepatitis constitutes a global threat. In many Balkan and Mediterranean countries, the disease burden due to…”
Get full text

Letter: renal tubular dysfunction during nucleotide analogue therapy in chronic hepatitis B by Manolakopoulos, S., Striki, A., Papatheodoridis, G. V.

Get full text

The usefulness of transient elastography in the assessment of patients with HBeAg-negative chronic hepatitis B virus infection by Papatheodoridis, G. V., Manolakopoulos, S., Margariti, A., Papageorgiou, M. V., Kranidioti, H., Katoglou, A., Kontos, G., Adamidi, S., Kafiri, G., Deutsch, M., Pectasides, D.

“…Summary Histological severity is often mandatory for the management of HBeAg‐negative chronic HBV patients. We evaluated the performance of transient…”
Get full text

Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection by Papatheodoridis, G V, Hadziyannis, E, Tsochatzis, E, Chrysanthos, N, Georgiou, A, Kafiri, G, Manolakopoulos, S, Tiniakos, D G, Giannousis, I, Manesis, E K, Archimandritis, A J

“…In chronic hepatitis C and non-alcoholic fatty liver disease, apoptotic caspases are activated in liver, and serum caspase activity has been suggested as a…”
Get more information

Platelets represent an independent predictor of sustained virological response (SVR) in patients with advanced chronic hepatitis C (CHC) treated with current direct acting antiviral(s) (DAA). HERACLIS: Hellenic multicenter real-life cohort study by Papatheodoridis, G, Kapatais, A, Sinakos, E, Elefsiniotis, I, Goulis, J, Deutsch, M, Vlachogiannakos, J, Dalekos, G, Koskinas, J, Karatapanis, S, Schina, M, Manesis, E, Ketikoglou, I, Sevastianos, V, Triantos, C, Cholongitas, E, Papageorgiou, M.-V, Kourikou, A, Karaoulani, T, Evangelidou, E, Koukoufiki, A, Karagiannakis, D, Gatselis, N, Tampaki, M, Ntetskas, G, Tsolias, C, Voulgaris, T, Ioannidou, P, Akriviadis, E, Manolakopoulos, S

Get full text

Quantitative Detection of the M204V Hepatitis B Virus Minor Variants by Amplification Refractory Mutation System Real-Time PCR Combined with Molecular Beacon Technology by Ntziora, F, Paraskevis, D, Haida, C, Magiorkinis, E, Manesis, E, Papatheodoridis, G, Manolakopoulos, S, Beloukas, A, Chryssoy, S, Magiorkinis, G, Sypsa, V, Hatzakis, A

“…Mutations in the highly conserved tyrosine-methionine-aspartate-aspartate (YMDD) motif are frequently associated with resistance to antivirals and represent a…”
Get full text

Cirrhosis but not neutropenia is associated with the development of infection in patients with chronic hepatitis C undergoing treatment with pegylated interferon-alpha and ribavirin by Striki, A., Manolakopoulos, S., Deutsch, M., Mela, M., Kalafateli, M., Schini, M., Anagnostou, O., Triantos, C., Andreadis, I., Ketikoglou, I., Papatheodoridis, G., Pectasides, D.

“…Summary Peginterferon‐alpha (PegIFNa) frequently causes neutropenia, mainly due to bone marrow suppression. The aim of this study was to explore factors that…”
Get full text

P0641 : Excellent 5-year survival in caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy and the impact of hepatocellular carcinoma (HCC) by Papatheodoridis, G, Dalekos, G, Yurdaydin, C, Buti, M, Sypsa, V, Goulis, J, Calleja, J.L, Chi, H, Manolakopoulos, S, Mangia, G, Gatselis, N, Keskın, O, Savvidou, S, De La Revilla, J, Hansen, B.E, Vlachogiannakos, I, Galanis, K, Idılman, R, Colombo, M, Esteban, R, Janssen, H.L, Lampertico, P

Get full text

Long‐term therapy with adefovir dipivoxil in hepatitis B e antigen‐negative patients developing resistance to lamivudine by MANOLAKOPOULOS, S., BETHANIS, S., KOUTSOUNAS, S., GOULIS, J., VLACHOGIANNAKOS, J., CHRISTIAS, E., SAVERIADIS, A., PAVLIDIS, C., TRIANTOS, C., CHRISTIDOU, A., PAPATHEODORIDIS, G., KARAMANOLIS, D., TZOURMAKLIOTIS, D.

“…Summary Background  The efficacy of long‐term adefovir dipivoxil monotherapy or combination of adefovir and lamivudine in hepatitis B e antigen…”
Get full text

P1075 PAGE-B: RISK SCORE FOR HEPATOCELLULAR CARCINOMA (HCC) DEVELOPMENT IN CAUCASIAN CHRONIC HEPATITIS B (CHB) PATIENTS RECEIVING ENTECAVIR (ETV) OR TENOFOVIR (TDF) by Papatheodoridis, G.V, Dalekos, G, Sypsa, V, Yurdaydin, C, Buti, M, Goulis, J, Arends, P, Manolakopoulos, S, Mangia, G, Gatselis, N, Keskın, O, Savvidou, S, Hansen, B.E, Papaioannou, C, Galanis, K, Idılman, R, Colombo, M, Esteban, R, Janssen, H.L.A, Lampertico, P

Get full text

Serum HCV RNA levels and HCV genotype do not affect insulin resistance in nondiabetic patients with chronic hepatitis C: a multicentre study by TSOCHATZIS, E., MANOLAKOPOULOS, S., PAPATHEODORIDIS, G. V., HADZIYANNIS, E., TRIANTOS, C., ZISIMOPOULOS, K., GOULIS, I., TZOURMAKLIOTIS, D., AKRIVIADIS, E., MANESIS, E. K., ARCHIMANDRITIS, A. J.

“…Summary Background  Chronic hepatitis C (CHC) induces insulin resistance (IR) and subsequently diabetes. Aim  To examine viral, metabolic and histological…”
Get full text

1354 HEPATITIS C VIRUS REINFECTION FOLLOWING SUSTAINED VIROLOGICAL RESPONSE IN INTRAVENOUS DRUG USERS by Manolakopoulos, S, Kranidioti, H, Karatapanis, S, Tsirogianni, E, Goulis, J, Deutsch, M, Anagnostou, O, Margaritopoulos, D, Papatheodoridis, G, Pectasides, D

Get full text

852 NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) MAY DEVELOP IN PATIENTS WITH NORMAL BODY MASS INDEX (BMI) by Margariti, E, Deutsch, M, Manolakopoulos, S, Kaflri, G, Tiniakos, D, Papatheodoridis, G.V

Get full text